id coadministration of ribociclib with halogenated anesthetics due to an increased risk for QT prolongation. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. Halogenated anesthetics can also prolong the QT interval. Concomitant use may increase the risk for QT prolongation.
Desipramine: (Major) Avoid coadministration of ribociclib with desipramine due to an increased risk for QT prolongation. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. Tricyclic antidepressants (TCAs) share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). Concomitant use may increase the risk for QT prolongation.
Deutetrabenazine: (Major) Avoid coadministration of deutetrabenazine with ribociclib. Clinically relevant QT prolongation may occur with deutetrabenazine. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. These ECG changes occurred within the first 4 weeks of treatment and were reversible with dose interruption.
Dexamethasone: (Moderate) Use caution if coadministration of ribociclib with dexamethasone is necessary, as the systemic exposure of dexamethasone may be increased resulting in increase in treatment-related adverse reactions. Exposure to ribociclib may also decrease, resulting in decreased efficacy. Ribociclib is a moderate CYP3A4 inhibitor and CYP3A4 substrate; dexamethasone is a CYP3A4 substrate and inducer.
Dexchlorpheniramine; Dextromethorphan; Pseudoephedrine: (Moderate) Use caution if coadministration of ribociclib with dextromethorphan is necessary, as the systemic exposure of dextromethorphan may be increased resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and dextromethorphan is a CYP3A4 substrate.
Dexlansoprazole: (Minor) Use caution if coadministration of ribociclib with dexlansoprazole is necessary, as the systemic exposure of dexlansoprazole may be increased resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and dexlansoprazole is a CYP3A4 substrate.
Dextromethorphan: (Moderate) Use caution if coadministration of ribociclib with dextromethorphan is necessary, as the systemic exposure of dextromethorphan may be increased resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and dextromethorphan is a CYP3A4 substrate.
Dextromethorphan; Diphenhydramine; Phenylephrine: (Moderate) Use caution if coadministration of ribociclib with dextromethorphan is necessary, as the systemic exposure of dextromethorphan may be increased resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and dextromethorphan is a CYP3A4 substrate.
Dextromethorphan; Guaifenesin: (Moderate) Use caution if coadministration of ribociclib with dextromethorphan is necessary, as the systemic exposure of dextromethorphan may be increased resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and dextromethorphan is a CYP3A4 substrate.
Dextromethorphan; Guaifenesin; Phenylephrine: (Moderate) Use caution if coadministration of ribociclib with dextromethorphan is necessar |
